Overview

Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)

Status:
Completed
Trial end date:
2010-04-14
Target enrollment:
Participant gender:
Summary
This study will determine whether the plasma concentration-time profile and pharmacokinetics (PK) of suvorexant (MK-4305) in participants with moderate and mild hepatic insufficiency are similar to those observed in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Suvorexant